Tumor 'Avatars' in a dish could help pick better chemo for kids with rare cancers
NCT ID NCT07528079
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new way to choose chemotherapy for children with high-risk or relapsed soft tissue sarcomas. Doctors grow a miniature version of the patient's tumor in the lab (called an organoid) and test different drugs on it to see which works best. The goal is to see if this personalized approach leads to more tumors shrinking or disappearing. The study involves 30 children aged 1 to 18 whose cancer has not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy drugs chosen based on organoid drug sensitivity testing
- What this could lead to
- If successful, this approach could help doctors select more effective chemotherapy for children with resistant sarcomas, potentially improving tumor shrinkage and delaying progression.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. The organoid predictions might not always match real patient responses, and chemotherapy side effects remain a risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can AI read tumor slides to outsmart childhood cancer?
- Ultrasound, CT, and MRI put to the test for identifying childhood neck lumps
- A simple blood test may reveal how ewing sarcoma responds to therapy
- Combination drug approach aims to tackle tough childhood cancer